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INTRODUCTION
In patients with coronary artery diseases in which prompt 
coronary revascularization is required before a major noncar-
diac surgery, current guidelines recommend the use of balloon 
angioplasty, bare-metal stent (BMS) implantation, or coro-
nary artery bypass graft (CABG), although the expanded use 
thereof in real-world practice is challenging due to their own 
various limitations.1,2 In the case of preoperative CABG, it is of-
ten a burden to patients to undergo two consecutive major sur-
geries (CABG and planned major noncardiac surgery) in a 
short period of time. This burden can be even greater in cases 
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Purpose: The present study aimed to evaluate the efficacy and safety of polymer-free drug-coated BioFreedom stent implantation 
in comparison to coronary artery bypass graft (CABG) before major noncardiac surgery.
Materials and Methods: In a multicenter registry, 55 patients required revascularization before major noncardiac surgery that 
should not be delayed >6 months. Of them, 27 underwent BioFreedom stent implantation and 28 underwent CABG. Primary out-
comes included rate of noncardiac surgery, time from revascularization to noncardiac surgery, and occurrence of composite out-
comes (all-cause death, myocardial infarction, stent thrombosis, stroke, repeat revascularization, or major bleeding).
Results: The rate of major noncardiac surgery was significantly higher in the BioFreedom group (92.6%) than in the CABG group 
(64.3%; p=0.027). Time from revascularization to noncardiac surgery was significantly shorter in the BioFreedom group (38.0 days) 
than in the CABG group (73.0 days; p=0.042). During the hospitalization for revascularization period, the occurrence of primary 
outcomes did not differ between the groups. However, the BioFreedom group showed a shorter hospitalization period and lower 
total treatment cost than the CABG group. During the hospital stay for noncardiac surgery, the occurrence of composite outcome 
was not significantly different between groups (4% vs. 0%; p>0.999): stroke occurred in only 1 case, and there were no cases of 
death or stent thrombosis in the BioFreedom group. 
Conclusion: This study demonstrated that BioFreedom stenting as a revascularization strategy before major noncardiac surgery 
might be feasible and safe in selected patients with less severe coronary artery diseases.
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in which urgent surgery is needed, such as cancer. With drug-
eluting stents (DES), elective surgery is recommended to be 
delayed for >6 months upon their implantation. Polymer- and 
carrier-free Biolimus A9−coated stent (BioFreedom, Biosen-
sors Interventional Technologies, Singapore) implantation 
with 1-month dual antiplatelet therapy (DAPT) was recently re-
ported to be safe and effective for patients with a high risk of 
bleeding.1-4 Because of a need for a shorter DAPT duration, its 
application before noncardiac surgery could be possible, al-
though no data are available to demonstrate this.3,4 Therefore, 
we sought to evaluate the outcomes after percutaneous coro-
nary intervention (PCI) with BioFreedom stent implantation 
for patients requiring coronary revascularization before a ma-
jor noncardiac surgery, compared with CABG, a standard 
treatment strategy, before noncardiac surgery.
MATERIALS AND METHODS
This multicenter study was conducted using data from the Ko-
rean Multicenter Angioplasty Team registry.5,6 The study pro-
tocol followed the Declaration of Helsinki, and was approved 
by the Institutional Review Boards of the participating hospi-
tals (IRB No. 4-2015-1094). All study subjects provided informed 
consent for their participation in the study. Patients who met all 
of the following criteria were finally analyzed: 1) candidate for 
intermediate- to high-risk noncardiac surgery; 2) candidate for 
noncardiac surgery deemed impossible to delay for >3–6 months 
by noncardiac surgeons; 3) completion of coronary evaluation 
as recommended in current guidelines;1,7 and 4) patients requir-
ing revascularization before noncardiac surgery due to the pres-
ence of acute coronary syndrome or stable angina with re-
duced left ventricular ejection fraction <45%, proven ischemia, 
unstabilized chest pain, or left main artery involvement, based 
on the recommendations of current guidelines.1,7 Patients who 
did not meet these criteria or those with coronary disease un-
suitable for both CABG and PCI were excluded. Between Jan-
uary 2016 and March 2017, a total of 8173 patients consulted 
the cardiology division for a preoperative cardiovascular eval-
uation before a major noncardiac surgery, and 55 eligible pa-
tients required coronary revascularization before noncardiac 
surgery, including 27 who underwent BioFreedom stent im-
plantation (BioFreedom group) and 28 who underwent bypass 
surgery (CABG group) upon discussion among a multidisci-
plinary heart team, noncardiac surgery department, patients, 
and family members. There was no BMS implantation or plain 
old balloon angioplasty case during the study period. Details 
on the flow of the study are provided in Fig. 1.
All study patients remained on DAPT, consisting of aspirin 
100 mg and clopidogrel 75 mg, until 5−7 days before noncardi-
ac surgery. The timing of noncardiac surgery was finally decid-
ed based on the multidisciplinary discussion of the heart team, 
including primary attending physicians, cardiac surgeons, and 
noncardiac surgery department members, who considered 
the patients’ opinions and medical conditions.
The primary outcomes were as follows: 1) rate of noncardiac 
surgeries finally performed and 2) composite of major clinical 
adverse events, including all-cause death, myocardial infarc-
tion (MI), stent thrombosis, stroke, repeat revascularization, or 
major bleeding during hospitalization for noncardiac surgery.
The secondary outcomes were as follows: 1) the time from 
coronary revascularization to noncardiac surgery; 2) time from 
index coronary angiography to revascularization; 3) a com-
posite of major clinical adverse events during hospitalization 
for revascularization and during the total study period, from 
the initial angiography to the last hospital visit; 4) major or mi-
nor bleeding; and 5) total hospitalization costs for revascular-
ization and noncardiac surgery.
Clinical events were defined by the Academic Research Con-
sortium.8,9 All deaths were considered to be of cardiac origin 
unless a definite noncardiac cause was established. MI was 
defined as an elevation of creatine kinase-MB above the upper 
normal limit (UNL) or a troponin T/I level >99th percentile of 
the UNL with concomitant ischemic symptoms or electrocar-
8173 patients consulted the cardiology division for preoperative cardiovascular 
         evaluation before major noncardiac surgery from Jan 2016 to Mar 2017
A total of 55 patients fulfilling criteria underwent coronary revascularization (PCI or CABG) 
before major noncardiac surgery
BioFreedom group (n=27) CABG group (n=28)
7086 did not meet the indication for coronary evaluation
  821 low-risk noncardiac surgery
  172    decided to undergo noncardiac surgery without PCI after coronary 
angiography
    39 decided to delay over 3−6 months or cancel noncardiac surgery
Fig. 1. Study flow. PCI, percutaneous coronary intervention; CABG, coronary artery bypass graft.
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diographic findings indicative of ischemia unrelated to an in-
terventional procedure. Cardiac enzymes were measured dur-
ing revascularization, and perioperative hospitalization and 
peak levels were analyzed. Stent thrombosis was defined as 
definite or probable stent thrombosis. Stroke event was defined 
as an acute neurological deficit of vascular etiology lasting >24 h.10 
Bleeding was classified by Thrombolysis in Myocardial Infarc-
tion risk score.11 The planned surgeries were classified accord-
ing to their clinical urgency into urgent (category 1: admission 
within 30 days desirable), semi-urgent (category 2: admission 
within 90 days desirable), and indolent (category 3: admission 
at some time in the future acceptable).12 To assess cardiac oper-
ative risk, the European system for cardiac operative risk eval-
uation (EuroSCORE) II was obtained.13 Coronary lesion com-
plexity was expressed as Synergy between PCI with Taxus and 
Cardiac Surgery (SYNTAX) score,14 for which an analysis was 
performed at an independent core laboratory (Cardiovascular 
Research Center, Seoul, Korea). Hospitalization cost was as-
sessed as total uninsured medical expenses.
Categorical variables are expressed as numbers and percent-
ages, and were compared using the chi-square test or Fisher’s 
exact test. Continuous variables are expressed as a mean±st-
andard deviation, and were compared with analysis of vari-
ance. Logistic regression analysis was performed to assess the 
major determinants of PCI versus CABG as the revasculariza-
tion strategy. Variables with p values <0.1 in univariate analy-
sis, revised cardiac risk index, which may be an important fac-
tor in the decision to perform cardiac surgery, and SYNTAX 
score were entered in the multivariable model as covariates. 
We evaluated clinical composite outcomes as time to first event 
analyses. Hazard ratios (HRs) with 95% confidence intervals 
(CIs) were determined, and the cumulative event rates were 
compared with Kaplan-Meier and Cox proportional hazard 
models with treatment strategy as fixed-effect factors. HRs, 95% 
CIs, and two-sided p values were calculated using Cox models. 
All statistical analyses were performed using R software, version 
3.3.2 (R Foundation for Statistical Computing, Vienna, Aus-
tria). p values <0.05 were considered statistically significant.
RESULTS
Baseline characteristics are shown in Table 1. Compared with 
the CABG group, the BioFreedom group had a lower incidence 
of history of PCI, a lower proportion of three-vessel disease and 
chronic total occlusion (CTO), and a lower SYNTAX score. The 
types of planned noncardiac surgeries did not differ signifi-
cantly between the two groups.
In the multivariate analysis for the determinants of PCI ver-
sus CABG, history of PCI [odds ratio (OR)=65.99; 95% CI= 
2.52−13645.94; p=0.042], CTO (OR=7.82; 95% CI=1.15−70.52; 
p=0.044), and a higher SYNTAX score (OR=1.19; 95% CI= 
1.02−1.45; p=0.043) were significant factors that favored CABG, 
while history of stroke (OR=0.01; 95% CI=0.00−0.45; p=0.048) 
was a significant determinant of PCI (Fig. 2).
A detailed explanation of the revascularization procedures 
performed in both groups is provided in Table 2. The time from 
initial coronary angiography to revascularization was shorter 
in the BioFreedom group than in the CABG group (p <0.001). 
Table 1. Baseline Characteristics
Variables
BioFreedom 
(n=27)
CABG
 (n=28)
p value
Age (yr) 71.5±7.4 69.7±6.8 0.341
Male 19 (70.4) 24 (85.7) 0.293
Hypertension 18 (66.7) 19 (67.9) >0.999
Diabetes mellitus   9 (33.3) 14 (50.0) 0.327
Chronic kidney disease   5 (18.5)   8 (28.6) 0.576
Chronic obstructive lung disease   1 (3.7)   4 (14.3) 0.370
Current smoker 11 (40.7)   7 (25.0) 0.339
Previous percutaneous coronary 
  intervention
  1 (3.7)   8 (28.6) 0.033
Previous ischemic stroke   5 (18.5)   1 (3.6) 0.179
Revised cardiac risk index 0.090
1 15 (55.6)   8 (28.6)
2   9 (33.3) 12 (42.8)
≥3   3 (11.1)   8 (28.6)
EuroSCORE II (%)   1.2±0.5   1.2±0.5 0.749
Left ventricular ejection fraction (%) 62.3±11.6 54.5±12.9 0.023
Clinical presentation 0.914
Stable angina 10 (37.0) 11 (39.3)
Unstable angina 13 (48.1) 12 (42.9)
Acute myocardial infarction   4 (14.8)   5 (17.9)
No. of diseased vessels 0.024
1 10 (37.0)   5 (17.9)
2 11 (40.7)   6 (21.4)
3   6 (22.3) 17 (60.7)
Treated vessel, left anterior  
  descending
24 (88.9) 27 (96.4) 0.577
Left main involvement   9 (33.3) 11 (39.3) 0.858
Chronic total occlusion   3 (11.1) 19 (67.9) <0.001
Bifurcation   6 (22.2)   9 (32.1) 0.601
SYNTAX score 14.7±5.8 23.2±9.2 <0.001
0−22 25 (92.6) 16 (57.1) 0.008
23−32   2 (7.4)   7 (25.0)
≥33   0 (0)   5 (17.9)
Details of the planned noncardiac surgery
Classification by urgency 0.275
Urgent 20 (74.1) 21 (75.0)
Semi-urgent   5 (18.5)   2 (7.1)
Indolent   2 (7.4)   5 (17.9)
Cancer surgery 16 (59.3) 18 (64.3) 0.916
CABG, coronary artery bypass graft; SYNTAX, Synergy between PCI with 
Taxus and Cardiac Surgery.
Values are presented as a n (%) or mean±standard deviation. 
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The BioFreedom group had fewer revascularized vessels (p< 
0.001) and a lower complete revascularization rate (p=0.025) 
than the CABG group. While there were no significant inter-
group differences in clinical events (Table 2), the BioFreedom 
group demonstrated fewer bleeding complications (0% vs. 
17.8%; p=0.067) and less frequent transfusions than the CABG 
group. Regarding medical expenses for revascularization, the 
BioFreedom group had a shorter mean hospital stay and low-
er overall cost than the CABG group (p<0.001).
After coronary revascularization, the rate of noncardiac sur-
gery was significantly higher in the BioFreedom group (92.6%) 
than in the CABG group (64.3%; p=0.027). Among the patients 
who planned to have urgent (category 1) surgery, all patients 
in the BioFreedom group underwent noncardiac surgery after 
coronary revascularization; six patients in the CABG group 
(100% vs. 71.4%; p=0.032) did not undergo surgery after coro-
nary revascularization because of patient refusal (Table 3, Fig, 
3). Time from revascularization to noncardiac surgery was 
significantly shorter in the BioFreedom group than in the CABG 
group (38.0 days vs. 73.0 days; p=0.042). Total time from diag-
nostic coronary angiography to noncardiac surgery was also 
significantly shorter in the BioFreedom group than in the 
Previous stroke
Previous PCI
Chronic total occlusion
LV ejection fraction
SYNTAX score
Revised cardiac risk index
   2
   >2
  0.01 (0.00−0.45)  0.048
65.99 (2.52−13645.94)  0.042
  7.82 (1.15−70.52)  0.044
  0.98 (0.88−1.09)  0.666
  1.19 (1.02−1.45)  0.043
  1.22 (0.12−12.37)  0.863
  7.26 (0.20−484.75)  0.305
Adjusted OR (95% CI)    p value
Decision to PCI      Decision to CABG
0.01     0.1      1       10     100
Fig. 2. Independent determinants of PCI vs. CABG. PCI, percutaneous 
coronary intervention; CABG, coronary artery bypass graft; LV, left ven-
tricular; SYNTAX, Synergy between PCI with Taxus and Cardiac Sur-
gery; OR, odds ratio; CI, confidence interval.
Table 2. Revascularization Strategy and In-Hospital Outcomes
Variables BioFreedom (n=27) CABG (n=28) p value
Time from initial coronary angiogram to revascularization (days)  0 [0−0]      5.5 [2.0−17.5] <0.001
Revascularization
No. of vessel revascularized   1.3±0.5 2.3±0.8 <0.001
Total number of stents   1.3±0.5
Stent diameter (mm)   3.0±0.3
Stent length (mm) 23.6±7.2
No. of grafted vessels 2.6±1.2
Use of left internal thoracic artery      28 (100.0)
Off-pump surgery      28 (100.0)
Minimal invasive direct coronary bypass      3 (15.8)
Complete revascularization    16 (59.3)    25 (89.3) 0.025
In-hospital outcomes
Day of hospitalization  1 [1−2]    9 [8−12] <0.001
Complications
All-cause death 0 (0) 0 (0) >0.999
Myocardial infarction 0 (0) 0 (0) >0.999
CK-MB elevation >3×UNL    2 (7.4)    2 (7.1) >0.999
Repeat revascularization 0 (0) 0 (0) >0.999
Stroke 0 (0) 0 (0) >0.999
Any bleeding 0 (0)      5 (17.8) 0.067
Major 0 (0)      3 (10.7) 0.248
Minor 0 (0)    2 (7.1) 0.488
Transfusion    2 (7.4)      9 (32.1) 0.051
Hospitalization cost (United States dollar)       6510 [5779−7759]          26168 [24237−28734] <0.001
Discharge medication
Dual antiplatelet therapy      27 (100.0)      28 (100.0) 0.893
Statins      27 (100.0)      28 (100.0) 0.893
Beta blockers    22 (81.5)    25 (89.3) 0.661
Angiotensin converting enzyme or angiotensin receptor blockers    13 (48.1)    10 (35.7) 0.509
CABG, coronary artery bypass graft; CK-MB, creatine kinase-myocardial band; UNL, upper normal limit. 
Values are presented as a n (%), mean±standard deviation, or median [interquartile range].
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CABG group (40.0 days vs. 93.0 days; p<0.001) (Table 3, Fig. 3). 
The rate of noncardiac surgery performed after revasculariza-
tion within 2 months was significantly higher in the BioFree-
dom group than in the CABG group. Despite a shorter dura-
tion of DAPT after PCI and the need for the maintenance of 
antiplatelet drug therapy during surgery, the BioFreedom 
group had only one perioperative major adverse event (isch-
emic stroke), which did not differ significantly from the CABG 
group (4% vs. 0%; p>0.999) (Table 3). Hospitalization periods 
and costs were similar between the two groups. However, the 
BioFreedom group had lower overall hospital costs, covering 
both coronary revascularization and noncardiac surgery. A 
representative case from the BioFreedom group is shown in 
Supplementary Fig. 1 (only online).
There was no significant difference in the composite of ma-
jor clinical events between the BioFreedom and CABG groups 
Table 3. Execution, Delay, and Outcomes of Noncardiac Surgery
Variables BioFreedom (n=27) CABG (n=28) p value
Patients with noncardiac surgery finally performed       25 (92.6)       18 (64.3) 0.027
Rates of noncardiac surgery finally performed according to the types of surgery
Urgent 20/20 (100.0)* 15/21 (71.4)* 0.032
Semi-urgent     4/5 (80.0)*     2/2 (100.0)* >0.999
Indolent     1/2 (50.0)*     1/5 (20.0)* >0.999
Cancer surgery 16/16 (100.0)* 14/18 (77.8)* 0.140
Reasons for cancellation of noncardiac surgery (n)         2       10
Patient refusal after revascularization         1         6
Change of treatment strategy         1         2
Intracranial hemorrhage         0         2
Time from revascularization to noncardiac surgery (days)    38.0 [35.0−46.0]    73.0 [35.0−94.0] 0.042
Urgent surgery    38.5 [35.5−50.5]    77.0 [35.0−102.0] 0.083
Cancer surgery    39.5 [35.5−50.5]    79.5 [47.0−116.0] 0.021
Total time from diagnostic coronary angiography to noncardiac surgery (days)    40.0 [37.0−50.0]    93.0 [60.0−137.0] <0.001
Urgent surgery    40.5 [38.0−53.5]    89.0 [59.0−139.5] 0.002
Cancer surgery    41.0 [39.0−53.5]    97.5 [61.0−142.0] 0.002
Performing noncardiac surgery after revascularization
Within 1 month         4 (16.0)         3 (16.7) >0.999
Within 2 months       22 (88.0)         8 (44.4) 0.006
Antiplatelet therapy
Duration of dual antiplatelet therapy before surgery (days)    31.5±9.4    57.5±47.0 0.027
Maintenance of mono-antiplatelet drug during surgery       24 (96.0)         5 (27.8) <0.001
Perioperative clinical adverse events
Composite of major adverse events         1 (4.0)         0 (0) >0.999
All-cause death         0 (0)         0 (0) >0.999
MI or stent thrombosis         0 (0)         0 (0) >0.999
Stroke         1 (4.0)         0 (0) >0.999
Major bleeding         0 (0)         0 (0) >0.999
Post-operation cardiac enzyme analysis
Peak CK-MB values (ng/mL)      3.2±2.6      1.9±1.4 0.115
Peak troponin T values (pg/mL)       14±8       28±32 0.191
CK-MB elevation >UNL×3         0 (0)         0 (0) >0.999
Troponin T elevation >UNL         5 (35.7)         9 (75.0) 0.108
Other outcomes
Minor bleeding         0 (0)         4 (22.2) 0.052
Transfusion         4 (16.0)         5 (27.8) 0.578
Hospitalization period (days)    16.0±25.3    15.1±22.3 0.906
Hospitalization cost (United States dollar)   9318 [5112−11981] 10983 [9608−13580] 0.305
Total cost from revascularization to noncardiac surgery (United States dollar) 15347 [12436−18520] 36710 [31995−43000] <0.001
CABG, coronary artery bypass graft; MI, myocardial infarction; CK-MB, creatine kinase-myocardial band; UNL, upper normal limit.
Values are presented as a n (%), mean±standard deviation, or median [interquartile range].
*Rates according to the types of noncardiac surgery.
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(Table 4). However, bleeding occurred less frequently in the 
BioFreedom group than in the CABG group (p=0.038). A simi-
lar trend was identified among those patients who underwent 
noncardiac surgery.
     
DISCUSSION
This is the first study to compare overall outcomes between 
BioFreedom stent implantation and CABG among real-world 
patients requiring coronary revascularization before noncar-
diac surgery. This study demonstrated that BioFreedom stent 
implantation with a minimal DAPT duration was associated 
with a higher proceeding rate of planned noncardiac surgery, 
with a shorter delay, than CABG. The composite clinical out-
comes were not significantly different between the BioFree-
dom and CABG groups during hospital stay for revasculariza-
tion and noncardiac surgery. However, because BioFreedom 
stent implantation was performed in selected patients at a low-
er surgical risk than those who underwent CABG, it cannot be 
generalized to other patient populations.
For patients with coronary artery diseases requiring coro-
nary revascularization before major noncardiac surgery, cur-
rent guidelines recommend balloon angioplasty, BMS implan-
tation, or CABG. Although balloon angioplasty or BMS im-
plantation did not raise concerns related to DAPT discontinu-
ation, such treatment is available for simple lesions only and 
cannot be applied for multi-vessel and complex lesions, which 
were more frequently observed on coronary angiogram. CABG 
has been recommended as the initial standard strategy for the 
highest-risk patients with complex lesions before noncardiac 
surgery that should not be delayed.1,7,14 However, its use could 
pose disadvantages for high-risk patients, and may be difficult 
to apply universally for patients with simple lesions. In addi-
tion, because two major operations, CABG and noncardiac sur-
gery, should be consecutively performed, some patients could 
abandon the noncardiac surgery after CABG. In this study, the 
CABG group showed a significantly higher rate of cancellation 
of noncardiac surgery than the BioFreedom group (35.7% vs. 
7.4%, respectively; p=0.027), mainly due to patient refusal (60%). 
Even in cancer surgery, 22.2% of patients in the CABG group 
did not undergo their planned surgery. For similar reasons, the 
proportion of patients who underwent noncardiac surgery af-
ter CABG within 2 months was also lower than that of those 
who underwent the PCI strategy (44.4% vs. 88.0%, respectively; 
p=0.006). On the contrary, DES, which has shown efficacy and 
safety even in high-risk patients and complex lesions, could 
be suggested as the initial revascularization strategy before 
noncardiac surgery. However, because DES could introduce 
concerns of stent thrombosis in surgeries that should not be 
Fig. 3. Comparison of various time intervals and rates of noncardiac surgery performed between the BioFreedom group (A) and the coronary artery 
bypass graft (CABG) group (B). The curves indicate the rates of noncardiac surgery finally performed and the reasons for cancellation (black arrows) 
in either group.
A.  BioFreedom 
(n=27)
B. CABG (n=28)
Day to
revascularization
Revascularization
admission
Day to
planned surgery
Refusal (n=2)
Refusal (n=6)
Intracranial
hemorrhage
(n=2)
-10               0                 10                20               30                40                50                60                70                80                90               100
Time
(days)
Strategy
changed
(n=2)
1 days**
9 days**
0 days**
-5.5 days**
38 days*
73 days*
92.6% (n=25)*
64.3% (n=18)*
BioFreedom vs. CABG
*p<0.05, **p<0.001
Rates of noncardiac surgery finally performed:
92.6% vs. 64.3% (p=0.027)
Rate (%)
100
50
0
100
50
0
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delayed for >3−6 months and require DAPT discontinuation, 
guidelines do not recommend DES as the first-choice treat-
ment.1,7 Furthermore, unexpected requests with premature dis-
continuation of DAPT have been found to be relatively com-
mon and continuously proposed during the first year following 
DES implantation.15
The LEADERS FREE (Prospective Randomized Comparison 
of the BioFreedom Biolimus A9–Coated Stent versus the Ga-
zelle Bare-Metal Stent in Patients at High Bleeding Risk) trial 
demonstrated that the BioFreedom stent was superior to a BMS 
with respect to safety and efficacy end points when used with 
1 month of DAPT among patients at a high risk for bleeding 
who underwent PCI.3 From the outcomes of the LEADERS 
FREE trial, BioFreedom stent implantation with a 1-month 
DAPT could be a better alternative revascularization strategy 
for selective patients with less severe coronary artery lesions 
before noncardiac surgery than balloon angioplasty or BMS 
and a comparable strategy to CABG. In the present study, we 
evaluated the outcomes of BioFreedom stent implantation for 
selected low-risk patients with less complex lesions requiring 
coronary revascularization before noncardiac surgery and 
compared various parameters between PCI with BioFreedom 
versus CABG. In terms of safety, we found no significant dif-
ference in the occurrence of composite clinical outcomes be-
tween the BioFreedom and CABG groups during the hospital 
stay for revascularization and noncardiac surgery. Although 
the number of patients enrolled was small, no cases of stent 
thrombosis occurred in the BioFreedom group. In terms of ef-
ficacy, the BioFreedom group had a significantly higher pro-
ceeding rate of noncardiac surgery, a shorter time from revas-
cularization to noncardiac surgery, a shorter hospital stay, and 
a lower total cost during revascularization than the CABG group, 
suggesting that PCI with BioFreedom stents could be compa-
rable to CABG in some ways, but more advantageous in others.
Our findings should be interpreted cautiously. Most patients 
with CTO or a high SYNTAX score decided to undergo CABG 
before noncardiac surgery, rather than PCI. Previous studies 
revealed that CABG may be a better treatment option than 
PCI in cases of highly complex lesions.14,16 CABG led to a higher 
rate of complete revascularization, which may affect long-term 
clinical outcomes including mortality.17 While the maintenance 
of mono-antiplatelet therapy would be surely necessary after 
BioFreedom stenting with 1-month DAPT, CABG could be 
suitable in patients planning to undergo surgeries in closed ar-
eas, such as intracranial space or the spinal canal, which defi-
nitely require antiplatelet discontinuation.18 Nevertheless, use 
of the BioFreedom stent may be beneficial in cases of rapidly 
progressing disease requiring urgent surgery; PCI with BioFree-
dom stents before noncardiac surgery enables the surgeon to 
proceed with the preplanned surgery with a high probability 
Table 4. Comparison of Clinical Outcomes between the BioFreedom and CABG Group (Overall and Surgery-Performed Patients)
Clinical outcomes BioFreedom (n=27) CABG (n=28) HR (95% CI) p value
Overall populations
Follow-up duration 201.0 [141.5−376.0] 315.0 [212.0−408.5] - 0.117
Composite of major clinical adverse events (%/year) 1 (3.8) 3 (15.7) 0.34 (0.04−3.30) 0.332
Individual events
All-cause death 0 (0) 0 (0) - >0.999
MI or stent thrombosis 0 (0) 0 (0) - >0.999
Stroke 1 (3.8) 0 (0) - 0.200
Repeat revascularization 0 (0) 0 (0) - >0.999
Any bleeding 2 (10.9) 9 (47.2) 0.23 (0.05−1.06) 0.038
Major bleeding 0 (0) 3 (15.7) - 0.085
Minor bleeding 2 (10.9) 6 (31.5) 0.34 (0.07−1.71) 0.173
Clinical outcomes BioFreedom (n=25) CABG (n=18) HR (95% CI) p value
Patients performing noncardiac surgery
Follow-up duration 201.0 [153.0−375.0] 336.5 [238.0−409.0] - 0.046
Composite of major clinical adverse events (%/year) 1 (4.0) 1 (8.0) 0.72 (0.04−11.5) 0.815
Individual events
All-cause death 0 (0) 0 (0) - >0.999
MI or stent thrombosis 0 (0) 0 (0) - >0.999
Stroke 1 (4.0) 0 (0) - 0.266
Repeat revascularization 0 (0) 0 (0) - >0.999
Any bleeding 2 (11.9) 7 (56.0) 0.23 (0.05−1.10) 0.045
Major bleeding 0 (0) 1 (8.0) - 0.238
Minor bleeding 2 (11.9) 6 (48.0) 0.27 (0.05−1.36) 0.090
CABG, coronary artery bypass graft; HR, hazard ratio; CI, confidence interval; MI, myocardial infarction. 
Values are presented as a n (events per 100-person-year), mean±standard deviation, or median [interquartile range].
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and shorter delay, which may have clinical implications in pre-
venting the progression of diseases, including cancer. PCI with 
a BioFreedom stent can be a good option to bring good clinical 
outcomes for selected patients awaiting noncardiac surgery. 
Considering the clinical significance and urgency of noncar-
diac surgery and cardiovascular risk, a multidisciplinary con-
sensus among cardiologists, cardiovascular surgeons, and 
noncardiac surgeons is important.
This study has some limitations. First, because it was a non-
randomized observational study consisting of a small popula-
tion, the possibility for actual clinical application in the real 
world is limited. In addition, the comparison of clinical adverse 
events between the two groups was underpowered due to small 
study populations. Furthermore, the SYNTAX scores differed 
from each group, which might have resulted in selection bias. 
Second, even though the final decision for coronary revascu-
larization was made following a full discussion of the heart 
team, surgeon, and patients and family members, there was 
no systematic uniform selection process. Third, the baseline 
characteristics of the two groups differed, and there were sev-
eral determinants for BioFreedom stents or CABG as the re-
vascularization strategy. The patients’ clinical conditions, le-
sion severity and complexity, and surgical urgency affected 
the decision and there could be unrevealed potential factors. 
For these reasons, the results of this study do not warrant the 
universal application of the revascularization strategy instead 
of CABG and the extended use of BioFreedom stents beyond 
the stated indications. However, this study implies the safety 
of PCI with BioFreedom for shorter duration until major non-
cardiac surgery is performed.
For conclusion, PCI with a BioFreedom stent might be a fea-
sible and safe therapeutic option in selected patients who re-
quire preoperative coronary revascularization with less severe 
coronary artery diseases. We found its use to be associated with 
a higher rate of undergoing planned surgery with shorter de-
lays and lower hospital costs, compared with CABG, as well as 
a low incidence of major cardiovascular and bleeding events 
after noncardiac surgery. However, a larger-scale study is need-
ed to validate our conclusions.
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